SGLT2 Drugs Tied to 18% Lower Death Risk for Kidney Patients 80 and Older, Though Heart Risks Rose

A study of more than 10,000 adults aged 80 and older with chronic kidney disease linked SGLT2 inhibitors to lower death and kidney-event risks, but also identified important safety concerns.